Diarrhea News and Research

Latest Diarrhea News and Research

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Dirty cash machines – Literally!

Experts have found that cash machines carry same amounts and kinds of bacteria as a public toilet. They took swabs from both places and found pseudomonads and bacillus bacteria types, both of which are behind common afflictions such as diarrhea.

11 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Floods may become a healthcare challenge, warns the AMA

The Australian Medical Association (AMA) has issued warnings to the Queensland health authorities to prepare for the rise of illnesses and injuries caused by the floods.

10 Jan 2011

Tips for surviving a bout with 'stomach flu'

A post-holiday crush of patients are crowding into area physician offices and hospital emergency rooms as individuals of all ages suddenly find themselves laid low by a highly contagious and quick-striking virus.

10 Jan 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Queensland’s flooded residents warned against insect bites

The Queensland Health authorities have issued warnings to residents and tourists in the Emerald region regarding mosquitoes, biting midges (commonly known as sand flies) and black flies in areas affected by flooding. The Council insect control programs are helping with reducing the number of insects, say authorities but people still need to protect themselves to reduce the risk of being bitten in the next few weeks.

6 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Violence against mothers increases risk of death among female children in India: Study

The deaths of 1.8 million female infants and children in India over the past 20 years are related to domestic violence against their mothers, according to a new study led by researchers at the Harvard School of Public Health.

6 Jan 2011

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease.

6 Jan 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

GLUMETZA tablets are now available to wholesalers and physicians

Santarus, and Depomed, today announced that supply of GLUMETZA® 500 mg to wholesalers and retailers has resumed. GLUMETZA is a once-daily, extended release formulation of metformin and is approved for use in adults with type 2 diabetes mellitus.

5 Jan 2011

Lancet editorial highlights similarities between current health challenges, those from 1911

"After a century of progress, the issues that medicine must tackle in the coming year aren't that different from the ones that faced doctors at the start of 1911, according to the observations" published Jan. 1 in a Lancet editorial, LiveScience reports (Parry, 12/30).

4 Jan 2011

C. difficile infection has become common among hospitalized children in the US

Hospitalized children in the United States are more frequently becoming infected with the bacteria Clostridium difficile, according to a report posted online today that will appear in the May print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Jan 2011

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).

29 Dec 2010

FDA warns against consumption of Tiny Greens brand Alfalfa Sprouts or Spicy Sprouts

The FDA is advising consumers not to eat Alfalfa Sprouts and Spicy Sprouts (which contain alfalfa sprouts mixed with radish and clover sprouts) from Tiny Greens Organic Farm of Urbana, Ill. The sprouts were distributed in 4 oz. and 5 lb. containers to various customers, including farmers' markets, restaurants and groceries, in Illinois, Indiana, Iowa, Missouri and possibly other Midwestern states.

28 Dec 2010

Diarrhea News and Research

Latest Diarrhea News and Research

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Dirty cash machines – Literally!

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

Floods may become a healthcare challenge, warns the AMA

Tips for surviving a bout with 'stomach flu'

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Queensland’s flooded residents warned against insect bites

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Violence against mothers increases risk of death among female children in India: Study

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

GLUMETZA tablets are now available to wholesalers and physicians

Lancet editorial highlights similarities between current health challenges, those from 1911

C. difficile infection has become common among hospitalized children in the US

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

FDA warns against consumption of Tiny Greens brand Alfalfa Sprouts or Spicy Sprouts

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Diarrhea News and Research

Latest Diarrhea News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in